Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Ohtuvayre is administered twice daily by a jet nebulizer, with sessions lasting between five minutes and seven minutes. Verona charges $2,950 for a monthly dose of Ohtuvayre. The $35,400 annual ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Program Updates and Key Milestones Ohtuvayre’s product specific J-code ... program for the maintenance treatment of COPD via a nebulizer. Results will support initiation of a Phase 2b trial ...